(4s,5r)-3-tert-butoxycarbony-2-(4-anisyl)-4- phenyl-5- oxazolidine carboxylic acid is used as the intermediate of Docetaxel.
Docetaxel is suitable for the treatment of locally advanced or metastatic breast cancer. Docetaxel is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer, even after the failure of cisplatin based chemotherapy.